Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials

Low-density lipoprotein cholesterol (LDL-C) reductions with the PCSK9 monoclonal antibody alirocumab may be affected by background statin dose due to increased PCSK9 levels with higher statin doses. Data from 8 Phase 3 trials conducted with background statin (n = 4629) were pooled by alirocumab dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Catapano, Alberico L., Lee, L. Veronica, Louie, Michael J., Thompson, Desmond, Bergeron, Jean, Krempf, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379546/
https://www.ncbi.nlm.nih.gov/pubmed/28374849
http://dx.doi.org/10.1038/srep45788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379546/
https://www.ncbi.nlm.nih.gov/pubmed/28374849
http://dx.doi.org/10.1038/srep45788

Ejemplares similares